Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions

Netherlands Heart Journal

Volumn 23, Issue 3, 2015, Pages 153-160

  Felix, Cordula ^a   Everaert, Bert ^a   Diletti, Roberto ^a   Van Mieghem, Nicolas ^a   Daemen, Joost ^a   Valgimigli, Marco ^a   De Jaegere, Peter P ^a   Zijlstra, Felix ^a   Regar, Evelyn ^a   Simsek, Cihan ^a   Onuma, Yoshinobu ^a   Van Geuns, Robert Jan M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABSORB BVS; Bioresorbable; Coronary artery disease; PCI; Review

Indexed keywords

ANGIOGRAPHY; BIORESORBABLE SCAFFOLD; CLINICAL EVALUATION; CORONARY BIFURCATION LESION; DRUG ELUTING STENT; FOLLOW UP; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; QUALITY OF LIFE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

EID: 84929795881     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-015-0652-2     Document Type: Review

References (32)

1. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193–202.
2. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J. 2014;35(12):765–76.
3. Nishio S, Kosuga K, Igaki K, et al. Long-Term (> 10 Years) clinical outcomes of first-in-human biodegradable poly-llactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012;125(19):2343–53.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
5. Yetgin T, van der Linden MM, de Vries AG, et al. Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Neth Heart J. 2014;22(2):55–61.
6. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation 6-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014;7(1):89–99.
7. Everaert B, Felix C, Koolen J, et al. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users. A position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart J. [Recommendation]. 2015. doi:10.1007/s12471-015-0651-3.
8. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897–910.
9. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6(10):999–1009.
10. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70(4):515–23.
11. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9(11):1271–84.
12. Ormiston JA, Serruys PW, Onuma Y, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. 2012;5(5):620–32.
13. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58(15):1578–88.
14. Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. JACC. 2014;64(22):2343–56.
15. Abizaid A, Costa JR, Jr., Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2014 Apr 29. PubMed PMID: 24769555. Epub 2014/04/29. Eng.
16. Chevalier B. An interim 12-month propensity adjusted comparison of clinical outcomes of ABSORB patients to Xience V patients. ESC. 2013.
17. Carrie D. An interim 24-month propensity score analysis comparison of clinical outcomes of ABSORB EXTEND and ABSORB Cohort B patients to Xience V patients. EuroPCR. 2014.
18. Whitbourn RJ. TCT-31 ABSORB EXTEND: an interim report on the 24-month clinical outcomes from the first 250 patients enrolled. J Am Coll Cardiol. 2013;62(18_S1):B11–B. doi:10.1016/j.jacc.2013.08.761.
19. Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164(5):654–63.
20. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2014 Sep 12. PubMed PMID: 25230593. Epub 2014/09/19. Eng.
21. Van Geuns RJ. BVS Expand: 6-month results. EuroPCR. 2014.
22. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2014 Jul 18.
23. Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention. 2014 Aug 20.
24. Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv. 2014 Jun 6.
25. Wohrle J, Naber C, Schmitz T, Schwencke C, Frey N, Butter C, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2014 Dec 16. PubMed PMID: 25499836. Epub 2014/12/17. Eng.
26. Eeckhout EE. Latest from ABSORB first. EuroPCR. 2014.
27. Ijkema BB, Bonnier JJ, Schoors D, Schalij MJ, Swenne CA. Role of the ECG in initial acute coronary syndrome triage: primary PCI regardless presence of ST elevation or of non-ST elevation. Neth Heart J. 2014;22(11):484–90.
28. Wiebe J, Mollmann H, Most A, et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103(2):141–8.
29. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35(12):777–86.
30. Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J. 2014;35(12):787–94.
31. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9(9):1036–41.
32. Dudek D, Rzeszutko L, Zasada W, Depukat R, Siudak Z, Ochala A, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes : the POLAR ACS study. Polskie Archiwum Medycyny Wewnetrznej. 2014 Dec 23;124(12):669–77. PubMed PMID: 25563622. Epub 2015/01/08. eng.